

CLINICAL PRACTICE

Caren G. Solomon, M.D., M.P.H., *Editor*

Adrenal Incidentaloma

Electron Kebebew, M.D.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

From the Division of General Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, CA. Address reprint requests to Dr. Kebebew at the Division of General Surgery, Department of Surgery, Stanford University School of Medicine, 300 Pasteur Dr., H3642, Stanford, CA 94305-2200, or at kebebew@stanford.edu.

N Engl J Med 2021;384:1542-51.

DOI: 10.1056/NEJMcp2031112

Copyright © 2021 Massachusetts Medical Society.

A 42-year-old woman has been in a motor vehicle accident in which her seat belt tightened. She has upper abdominal pain and is evaluated with computed tomography (CT). This imaging shows no evidence of intraabdominal trauma but reveals a well-circumscribed and homogeneous left adrenal mass that is 3.2 cm in diameter. The mass has an attenuation value of 7 Hounsfield units on unenhanced CT. The patient's history is remarkable for obesity and newly diagnosed mild hypertension. On physical examination, the blood pressure is 142/90 mm Hg. There is sternal and upper abdominal bruising but no striae, moon facies, or fat accumulation over the dorsocervical spine (buffalo hump). How should this patient be further evaluated and treated?

THE CLINICAL PROBLEM

ADRENAL INCIDENTALOMA IS DEFINED AS A CLINICALLY UNAPPARENT adrenal lesion (≥ 1 cm in diameter) that is detected on imaging performed for indications other than evaluation for adrenal disease.¹ This definition excludes patients who are undergoing screening and surveillance because of hereditary syndromes or those with known extraadrenal cancer who are undergoing imaging for staging or during follow-up after treatment.



An audio version
of this article
is available at
[NEJM.org](https://www.nejm.org)

Among adults, the prevalence of adrenal incidentaloma has been reported to be 1 to 6%,^{2,3} and the prevalence has increased with the growing use of and technological advances in imaging and with the aging of the population.^{4,5} The prevalence is higher among older adults, with a peak ($\leq 7\%$) in the fifth to seventh decades.³ Most adrenal incidentalomas are nonfunctioning benign tumors; 75% are nonfunctioning cortical adenomas.⁶⁻⁹ However, there are important clinical consequences in a subset of these masses. For example, approximately 14% of adrenal incidentalomas are functional tumors that secrete excess cortisol, aldosterone, or (rarely) both. Other masses with clinical significance are pheochromocytomas (approximately 7%) and primary adrenal cancers or metastases to the adrenal glands (approximately 4%).⁶⁻⁹ When an adrenal mass is incidentally identified, the key clinical questions are whether it is functioning and whether it is malignant. These determinations are guided by clinical and radiographic features and biochemical assessments.

STRATEGIES AND EVIDENCE

In the absence of randomized, controlled trials in which various approaches to evaluation are compared, the workup is guided by data from prospective and retrospective observational studies. A careful history taking and physical examination

KEY CLINICAL POINTS

ADRENAL INCIDENTALOMA

All patients with an adrenal mass that is discovered during diagnostic testing for another condition (an incidentaloma) should undergo biochemical testing to detect pheochromocytoma and excess cortisol secretion, and those who also have high blood pressure should undergo biochemical testing to detect primary hyperaldosteronism.

Patients with pheochromocytoma should undergo adrenalectomy after adequate presurgical alpha-blockade and beta-blockade, if necessary.

Patients with mild autonomous cortisol excess and primary hyperaldosteronism may benefit from adrenalectomy, but treatment should be individualized.

Nonfunctioning adrenal tumors that have an attenuation of 10 Hounsfield units or less on computed tomographic (CT) evaluation and that are smaller than 4 cm in greatest diameter generally do not warrant intervention or long-term follow-up.

All other adrenal incidentalomas with indeterminate features on imaging may warrant additional imaging with contrast-enhanced CT, magnetic resonance imaging with chemical-shift analysis, positron-emission tomography CT with ^{18}F -fluorodeoxyglucose, or all of these tests. The management of these masses should be individualized and should involve a multidisciplinary team consisting of an endocrinologist, an endocrine surgeon, and a radiologist.

focusing on signs and symptoms that may be associated with hormonal hypersecretion or cancer are essential (Fig. 1, and Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).

HORMONAL EVALUATION*Mild Autonomous Cortisol Excess*

Abnormal cortisol secretion that is independent of normal hypothalamic-pituitary control in the absence of overt clinical signs of Cushing's syndrome is called mild autonomous cortisol excess (also known as subclinical Cushing's syndrome). A careful history taking and physical examination should focus on determining whether the patient has had recent weight gain or has a history of easy bruising, general weakness, poor wound healing, or decreases in memory and cognitive function. The patient should also be evaluated for the presence of central obesity, purple striae, facial rounding and plethora, supraclavicular and dorsocervical fat pads, acne, and hirsutism.

Mild autonomous cortisol excess, the most common functional disorder detected in patients with adrenal incidentaloma, occurs in approximately 10% of such patients (range, 1 to 29), depending on the diagnostic criteria used and the population studied.^{3,6,7,9} Patients with mild autonomous cortisol excess have a higher incidence of coexisting conditions such as hypertension, obesity, glucose intolerance or type 2 diabetes mellitus, dyslipidemia, and osteopenia or

osteoporosis than patients with nonfunctioning adrenal tumors.¹⁰

An overnight dexamethasone (1 mg) suppression test should be performed in all patients with adrenal incidentaloma (Table 1). The most appropriate cutoff value for the morning serum cortisol level to make a diagnosis of mild autonomous cortisol excess is controversial. A level of more than 1.8 μg per deciliter (>50 nmol per liter) has high sensitivity (95 to 100%) but low specificity (60 to 80%), whereas a level of more than 5.0 μg per deciliter (>138 nmol per liter) has lower sensitivity (86%) but higher specificity (92 to 97%).^{3,7,11-13} Additional findings on biochemical tests (e.g., a low corticotropin level, an elevated 24-hour urinary cortisol level, a high late-night salivary cortisol level, and a low dehydroepiandrosterone sulfate level) may help to confirm the diagnosis and magnitude of cortisol excess (Table 1).¹⁴

In a meta-analysis assessing outcomes in 4121 patients with adrenal incidentalomas that were either nonfunctioning or were causing mild autonomous cortisol excess, the risk of progression to overt Cushing's syndrome was low (<0.1%) in both groups during a mean follow-up of 50.2 months.¹⁵ Furthermore, mild autonomous cortisol excess developed in only 4.3% of the patients with nonfunctioning tumors, and fewer than 0.1% of the patients with mild autonomous cortisol excess had spontaneous resolution during follow-up. The prevalence of type 2 diabetes mellitus, hypertension, obesity, dyslipidemia,




Figure 1. Treatment Algorithm for Patients with an Adrenal Incidentaloma.

Treatment should be individualized according to the patient's coexisting conditions, preferences, and the clinical expertise available. Hormonal evaluations and imaging should be performed in parallel. Adrenalectomy is not warranted for all patients; the care plan should be discussed by a multidisciplinary team considering the patient's coexisting conditions, response to medical treatment, and risk associated with adrenalectomy. Most adrenalectomies can be performed with a minimally invasive approach, but for a tumor that arouses suspicion for cancer, an open adrenalectomy is usually recommended. Adrenalectomy may be considered in patients with mild autonomous cortisol excess, depending on coexisting conditions and other factors, and it is generally recommended in patients who have cortisol levels higher than $5.0 \mu\text{g}$ per deciliter ($>138 \text{ nmol}$ per liter) after a 1-mg dexamethasone suppression test. Follow-up imaging at 6 months may be considered in patients younger than 40 years of age because adrenal incidentalomas are not common in this age group. ^{18}F -FDG PET-CT denotes ^{18}F -fluorodeoxyglucose positron-emission tomography computed tomography, MRI magnetic resonance imaging, and SUV_{max} maximum standardized uptake value.

vertebral fractures, and death were higher among patients with mild autonomous cortisol excess than among those with nonfunctioning adrenal incidentaloma at baseline. These conditions were more likely to develop in patients with nonfunctioning tumors and to worsen during follow-up in those with mild autonomous cortisol excess. In retrospective studies involving patients with adrenal incidentaloma, the risks of cardiovascular disease and death from any cause were higher

Table 1. Biochemical Evaluation in Patients with Adrenal Incidentaloma.*

Clinical Diagnosis	Screening Test	Additional or Confirmatory Test	Common Causes of False Positive or False Negative Findings	Special Considerations
Mild autonomous cortisol excess	Overnight dexamethasone (1 mg) suppression test; an abnormal result is a serum cortisol level >1.8 µg per deciliter (50 nmol per liter) with confirmation of serum dexamethasone level (to ensure adherence); a higher serum cortisol cutoff level (e.g., 3–5 µg per deciliter) can be used to reduce the risk of a false positive	Measurement of levels of morning serum corticotropin and cortisol levels, 24-hr urinary cortisol, late-night salivary cortisol, midnight serum cortisol, and DHEAS	False positives may occur in patients receiving medications that accelerate hepatic metabolism of dexamethasone and with nonadherence to dexamethasone	Consider a pseudo-Cushing's syndrome state due to diabetes, obesity, pregnancy, alcoholism, psychiatric disorders, or stress
Pheochromocytoma	Measurement of levels of plasma-free metanephrines or 24-hr urinary fractionated metanephrines	Not applicable	False positives may occur in patients with stress and illness warranting hospitalization; with medications that increase levels of endogenous catecholamines; with excessive caffeine; and with recreational drug use (e.g., amphetamines)	Biochemical testing may not be necessary if the adrenal mass has CT attenuation of ≤10 Hounsfield units; genetic testing for inherited syndrome should be performed, regardless of family history, if screening test is positive
Primary hyperaldosteronism	Measurement of mid-morning plasma aldosterone concentration and plasma renin activity; a ratio of plasma aldosterone concentration to plasma renin activity >20 confirms diagnosis	If the ratio of plasma aldosterone concentration to plasma renin activity <20, confirmatory testing includes 24-hr urinary aldosterone excretion test with patient receiving high-sodium diet, aldosterone suppression test, and testing with saline infusion while patient is sitting	False positives can be caused by beta-blockers, methylglucuronide, nonsteroidal anti-inflammatory drugs, and oral contraceptives and estrogen; false negatives can be caused by angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and potassium-sparing diuretics (e.g., spironolactone, eplerenone, and amiloride)	If patient is a candidate for adrenalectomy and >35 yr of age, adrenal venous sampling is recommended to confirm lateralization of aldosterone to the side of the adrenal mass (some patients have bilateral aldosterone hypersecretion, or the contralateral adrenal gland may be the source of excess aldosterone and the tumor detected is nonfunctioning)

* Reference ranges for specific assays based on age and sex should be used and may differ from the ranges shown here. DHEAS denotes dehydroepiandrosterone sulfate. Additional laboratory tests may include measurement of plasma chromogranin A levels, 24-hour urinary 3-methoxytyramine levels, or both, especially when a malignant pheochromocytoma is suspected because of the presence of potential metastatic disease sites or local invasion.




Figure 2. Imaging Features of Adrenal Masses.

Panel A (left image) shows an unenhanced CT scan that reveals a left adrenal mass (arrow) with high attenuation (>10 Hounsfield units). Panel A (right image) shows a left adrenal mass, presumed to be an adenoma (arrow), with low attenuation (≤ 10 Hounsfield units). Panel B shows a large heterogeneous left adrenal mass (arrows) with irregular borders and necrotic areas on enhanced CT. The pathological findings were consistent with adrenocortical carcinoma. Panel C (left image) shows MRI of a right pheochromocytoma (arrow) that was hyperintense on a T2-weighted image. Panel C (right image) shows a right adrenocortical carcinoma (arrows) with local invasion.

among those with mild autonomous cortisol excess (defined as a morning cortisol level $>1.8 \mu\text{g}$ per deciliter after a 1-mg dexamethasone suppression test) than among those with nonfunctioning tumors, and the risks were greater with higher morning cortisol levels ($>5.0 \mu\text{g}$ per deciliter vs. >1.8 to $5.0 \mu\text{g}$ per deciliter).¹⁶⁻²⁰

The care of patients with mild autonomous cortisol excess may involve active surveillance or adrenalectomy. Data comparing outcomes with the use of these strategies are limited. One small randomized, controlled trial comparing adrenalectomy (in 23 patients) with surveillance (in 22 patients) for mild autonomous cortisol excess showed that after surgery, there was normalization or improvement in the condition of patients with type 2 diabetes mellitus (in 5 of 8 patients [62%]), hypertension (in 12 of 18 patients [67%]), and hyperlipidemia (in 3 of 8 patients [38%]), as compared with no normalization or no improvement in these conditions in patients in the surveillance group.²¹ Three of 6 patients in the surgical group were reported to have postoperative decreases in obesity, whereas no changes in bone measures were seen in 5 patients who had osteoporosis; comparative data were lacking for the control group. In retrospective cohort studies, patients who underwent adrenalectomy had lower glucose levels and less hypertension and dyslipidemia than those who were cared for with surveillance.^{22,23}

Pheochromocytoma

Although pheochromocytoma may manifest as an adrenal incidentaloma, on careful history and

physical examination, many patients are found to have classic symptoms or signs of pheochromocytoma, a family history of these masses, or both. A total of 1.5 to 14.0% of adrenal incidentalomas are found to be pheochromocytomas.⁹ Imaging features on CT may be helpful in suggesting pheochromocytoma (Fig. 2). These features include an attenuation of more than 10 Hounsfield units on unenhanced CT, the presence of areas of increased vascularity and necrosis on enhanced CT, and delayed washout of contrast medium. On magnetic resonance imaging (MRI), pheochromocytoma may have high T2-weighted intensity (Fig. 2).

Guidelines recommend that all patients with adrenal incidentaloma undergo biochemical screening for pheochromocytoma because these tumors may be clinically silent.^{9,24-27} However, some investigators have suggested that biochemical screening for pheochromocytoma is not necessary in a patient who has a lipid-rich tumor with a CT attenuation of 10 Hounsfield units or less, because these tumors are rarely pheochromocytomas ($<0.5\%$ of cases).^{28,29} The most accurate screening tests to detect pheochromocytoma are measurement of the levels of plasma-free metanephrines (sensitivity, 89 to 100%, and specificity, 79 to 98%) or 24-hour urinary fractionated metanephrine level (sensitivity, 86 to 97%, and specificity, 69 to 95%).³⁰ To minimize the risk of perioperative illness and death, patients with a diagnosis of pheochromocytoma should undergo adrenalectomy only after sufficient alpha-blockade followed by beta-blockade, if necessary, is achieved (Fig. 1).

Primary Hyperaldosteronism

Among patients with adrenal incidentaloma, primary hyperaldosteronism is less common than mild autonomous cortisol excess and pheochromocytoma; primary hyperaldosteronism accounts for 1.6 to 3.3% of incidentalomas.⁹ However, any patient with adrenal incidentaloma and hypertension or hypokalemia should be screened for primary hyperaldosteronism with measurement of the mid-morning plasma aldosterone concentration and plasma renin activity; patients should not be taking medications that could cause false positive or false negative results (Table 1).³¹

Although studies have used various cutoff values to identify hyperaldosteronism, a ratio of the plasma aldosterone concentration to plasma renin activity that is higher than 20 is considered to be a reliable indicator of the diagnosis; if the ratio is high but below this level, confirmatory testing is recommended (Table 1).^{31,32} Once the diagnosis is established, patient-specific factors guide decisions regarding medical versus surgical therapy (Fig. 1).

Additional Hormonal Secretion

It is extremely rare for patients with adrenal incidentaloma to have sex hormone (estrogen or testosterone) secreting tumors without appreciable clinical manifestations. In women, excess testosterone is associated with features of virilization such as facial hair growth, acne, and deepening of the voice, and excess estrogen is associated with irregular uterine bleeding and breast tenderness. In men, estrogen-secreting tumors can cause gynecomastia, testicular atrophy, and decreased libido.

ASSESSMENT FOR CANCER

An adrenal incidentaloma may be a primary malignant tumor that has arisen from the adrenal cortex (adrenocortical carcinoma) or medulla (pheochromocytoma), or, rarely, a metastatic tumor. Adrenocortical carcinoma, which accounts for 1.2 to 11.0% of adrenal incidentalomas,⁹ depending on the study population, may secrete excess hormones or be nonfunctioning. Up to 21% of adrenal incidentalomas in patients with a history of or known current primary cancer indicate adrenal metastasis.^{9,33} Cancers that are most likely to spread to the adrenal glands are lung cancer, gastrointestinal cancer, melanoma, and renal-cell carcinoma.³³ Tumor size and imag-

ing features are key to determining the likelihood of cancer and guiding treatment (Table 2 and Figs. 1 and 2).

Tumor Size

Although many studies of the risks of cancer associated with tumor size are limited by small samples, retrospective design, and selection bias, data consistently support associations between tumors that are larger than 4 cm in greatest diameter and an increased risk of cancer among patients with a unilateral adrenal mass (Table 2).^{35,36} The risk of adrenocortical carcinoma is less than 2% among patients with tumors smaller than 4 cm in diameter, 6% among those with tumors between 4 cm and 6 cm in diameter, and 25% or higher among those with tumors that are at least 6 cm in diameter.³⁵ However, patient age is an important factor in estimating cancer risk; because benign incidentalomas are uncommon in patients younger than 40 years of age, cancer is a concern even with smaller tumors (<4 cm in diameter) in this age group. It is important to measure the adrenal tumor in three dimensions (the greatest length, width, and height) because two-dimensional (cross-sectional) measurements often underestimate size.

Imaging Features Suggestive of Cancer

On CT imaging, features other than tumor size can help to differentiate benign from malignant adrenal incidentalomas, although the ultimate diagnosis is based on histologic findings or clinical follow-up.^{34,37} Irregular tumor margins, heterogeneity, necrosis, vascularity, and calcification are features that arouse suspicion for cancer (Table 2). An attenuation of 10 Hounsfield units or less on unenhanced CT is consistent with a benign lesion; in a series of 1161 adrenal tumors with an attenuation of 10 Hounsfield units or less, no malignant tumors were observed.³⁸

In patients who have incidentalomas with an attenuation of more than 10 Hounsfield units, follow-up imaging may include contrast-enhanced CT (to measure the percentage of washout of contrast medium at various times), MRI with chemical-shift analysis, or positron-emission tomography (PET) CT with ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG). On contrast-enhanced CT, adenomas commonly enhance more rapidly and have faster washout of intravenous contrast medium when

Table 2. Imaging Features of Adrenal Incidentaloma.*

Feature	Adrenocortical Adenoma	Pheochromocytoma	Adrenocortical Carcinoma	Metastasis
Size	Usually small, <4 cm in diameter	Variable, frequently large	Large, usually >6 cm in diameter	Variable
Margins and shape	Smooth margins, round or oval	Smooth margins, round or oval	Irregular margins and shape	Irregular margins and shape
Consistency	Homogeneous	Most are heterogeneous (but small ones can be homogeneous)	Heterogeneous	Heterogeneous
Laterality	Usually unilateral but can be bilateral (in 15% of cases)	Usually unilateral but can be bilateral	Usually unilateral	Usually unilateral but can be bilateral
Unenhanced CT attenuation Hounsfield units	≤10	>10	>10	>10
Contrast-enhanced CT features				
Attenuation	Low	High	High	High
Vascularity	Low	High	High	Usually high
Washout	Fast	Slow	Slow	Slow
MRI features	Isointense in relation to liver on T2-weighted image; signal drop on chemical-shift imaging	Hyperintense in relation to liver on T2-weighted image; no signal drop on chemical-shift imaging	Markedly hyperintense in relation to liver on T2-weighted image; no signal drop on chemical-shift imaging	Hyperintense in relation to liver on T2-weighted image; no signal drop on chemical-shift imaging
¹⁸ F-FDG PET-CT features				
Avidity	Not avid	Avid	Avid	Avid
SUV _{max}	<5	Usually ≥5	Usually ≥5	Usually ≥5
Adrenal-to-spleen or adrenal-to-liver signal-intensity ratio	<1.0	≥1.0 1.5	≥1.0 1.5	≥1.0 1.5 but may vary based on primary origin of cancer
Necrosis, calcification, and hemorrhage	Uncommon	Hemorrhagic, necrotic, and cystic areas more common in larger tumors	Necrosis, calcification, and hemorrhage are common	Hemorrhagic, necrotic, and cystic areas more common in larger tumors

* Myelolipoma and adrenal cysts have typical imaging features on CT and or magnetic resonance imaging (MRI). ¹⁸F-FDG PET-CT denotes positron-emission tomography (PET) CT with ¹⁸F-fluorodeoxyglucose, and SUV_{max} maximum standardized uptake value.

The presence of metastasis is the only way to determine whether a pheochromocytoma is malignant. Metastatic pheochromocytoma is associated with larger tumors (>6 cm in diameter) and irregular margins.

Washout of contrast medium has been measured at various times (60 to 90 seconds [early] and 10 to 15 minutes [late]) with both relative and absolute values. Absolute washout is defined as the attenuation value in Hounsfield units on early enhanced CT minus Hounsfield units on delayed CT, divided by Hounsfield units on early enhanced CT, multiplied by 100%, and relative washout is defined as Hounsfield units on early enhanced CT minus Hounsfield units on delayed CT, divided by Hounsfield units on enhanced CT, multiplied by 100%. Absolute washout values greater than 60% and relative washout values greater than 40% suggest an adenoma.³⁴

Some studies have used an SUV_{max} cutoff value that is less than 5. The adrenal-to-spleen signal-intensity ratio (i.e., the signal intensity of the adrenal mass divided by the signal intensity of the spleen) and the adrenal-to-liver signal-intensity ratio (i.e., the signal intensity of the adrenal mass divided by the signal intensity of the liver) are based on meta-analyses and prospective studies.³⁴ Some studies have used adrenal-to-spleen or adrenal-to-liver SUV_{max} ratios.

measured at 60 to 90 seconds (early enhancement) and at 10 to 15 minutes (delayed enhancement) after the administration of contrast medium than adrenocortical carcinomas. Absolute washout is defined as the attenuation value in Hounsfield units on early enhanced CT minus Hounsfield units on delayed CT, divided by Hounsfield units on early enhanced CT minus Hounsfield units on unenhanced CT, multiplied by 100%, and relative washout is defined as Hounsfield units on early enhanced CT minus Hounsfield units on delayed CT, divided by Hounsfield units on enhanced CT, multiplied by 100%. Absolute washout of more than 60% of the contrast medium and relative washout of more than 40% of the contrast medium are suggestive of an adenoma, but the sensitivities and specificities of these cutoff values vary across studies owing to variations in technique and timing of measurement of washout.³⁴

MRI with chemical-shift analysis, which assesses qualitative loss of signal intensity, quantitative loss of signal intensity, or both between in-phase and out-of-phase imaging, is especially useful to avoid radiation exposure in pregnant women and children and in patients who are allergic to iodinated contrast medium. In a systematic review, qualitative (visual) analysis of the adrenal signal-intensity index and quantitative assessment of the adrenal-to-spleen ratio (i.e., the signal intensity of the adrenal mass divided by the signal intensity of the spleen) both had high accuracy (pooled sensitivities and specificities, 94% and 95%, respectively) for identifying adenomas.³⁷ In a meta-analysis of 29 studies, findings on ¹⁸F-FDG PET-CT adrenal imaging that determined the maximum standardized uptake value and the ratio of the maximum standardized uptake value in the adrenal tumor as compared with the spleen or liver effectively distinguished benign from malignant tumors (pooled sensitivities, 85 to 91%, and pooled specificities, 89 to 91%).³⁹

Adrenal Biopsy

Biopsy of an adrenal incidentaloma is rarely indicated,³³ since it has low accuracy for distinguishing benign from malignant adrenal tumors and may lead to tumor seeding if the mass is an adrenocortical carcinoma. An exception is the rare case in which adrenal metastasis is strongly suspected and biopsy confirmation would change the treatment plan; in such cases, biochemical

testing to exclude a pheochromocytoma should be performed first to avoid precipitation of a hyperadrenergic crisis by biopsy.

ASSESSMENT OF BILATERAL ADRENAL MASSES

Approximately 15% of patients with adrenal incidentaloma have bilateral adrenal masses.⁴⁰ The differential diagnosis of bilateral adrenal masses includes primary bilateral macronodular adrenal hyperplasia and adenomas, bilateral pheochromocytomas, congenital adrenal hyperplasia, bilateral adrenal hyperplasia due to Cushing's disease or ectopic corticotropin secretion, metastases or primary cancers, myelolipomas, infections, hemorrhage, and partial glucocorticoid resistance. In addition to the hormonal assessments described for a solitary adrenal incidentaloma, measurement of the serum 17-hydroxyprogesterone level is indicated to rule out congenital adrenal hyperplasia.⁴¹ In addition, if bilateral adrenal masses appear on imaging to be hemorrhagic or infiltrative, the patient should undergo testing for adrenal insufficiency. In patients with bilateral adrenal masses, the imaging characteristics of each adrenal lesion should be evaluated independently in determining appropriate management.

FOLLOW-UP IN PATIENTS WITH NONFUNCTIONING LESIONS

Nonfunctioning adrenal incidentalomas with features that are consistent with an adenoma on imaging (≤ 10 Hounsfield units) and that are smaller than 4 cm in greatest diameter usually have a benign course and do not warrant additional follow-up imaging. In a meta-analysis involving 4121 patients with nonfunctioning adrenal lesions, the mean tumor growth was 2 mm over a median of 52.8 months of follow-up; only 2.5% of the patients had tumor enlargement of 1 cm or more, and adrenocortical carcinoma did not develop in any of the patients.¹⁵

Follow-up with imaging and biochemical tests is recommended for patients with nonfunctioning tumors with indeterminate features on imaging. However, the most appropriate time intervals for reassessment are unclear, and they vary among different guidelines.

AREAS OF UNCERTAINTY

The diagnostic criteria for and management of mild autonomous cortisol excess are uncertain.

More data are needed to better identify patients with metabolic abnormalities that are most likely to be related to the adrenal lesion and to reverse the metabolic abnormalities with surgery. Studies are lacking to compare outcomes of various follow-up strategies for patients who have a nonfunctioning adrenal incidentaloma with intermediate imaging features.

GUIDELINES

Guidelines for the management of adrenal incidentaloma have been published by several professional societies.^{9,24-27} All recommend biochemical testing to rule out functional tumors (mild autonomous cortisol excess, pheochromocytoma, and primary hyperaldosteronism) at the initial evaluation. However, guidelines vary in the criteria recommended to diagnose mild autonomous cortisol excess and the need for additional biochemical testing, the other imaging recommended when further evaluation is needed, and the criteria for adrenal tumor size used to recommend adrenalectomy for nonfunctioning tumors, although recent guidelines support a cut-off value of 4 cm in diameter. Guidelines also differ with respect to follow-up recommendations for nonfunctioning tumors that are smaller than 4 cm in diameter with attenuation of 10 Hounsfield units or less, but the most recent guidelines recommend that no follow-up imaging is needed unless clinical manifestations develop.⁹ The present recommendations are generally concordant with most of these guidelines.⁹

CONCLUSIONS AND RECOMMENDATIONS

The patient described in the vignette has an adrenal incidentaloma that is 3.2 cm in diameter

with an attenuation of less than 10 Hounsfield units on unenhanced CT. A comprehensive history and physical examination should be performed to look for evidence of excess adrenal hormonal secretion. Biochemical testing is warranted to rule out mild autonomous cortisol excess, pheochromocytoma, and, given that the patient has hypertension, primary hyperaldosteronism.

If the patient has pheochromocytoma, she should undergo a unilateral minimally invasive adrenalectomy (open if imaging features arouse suspicion for cancer) after pretreatment. If biochemical testing shows mild autonomous cortisol excess or primary hyperaldosteronism, imaging features arouse suspicion for cancer, or both, involvement of a multidisciplinary team including an endocrinologist, a radiologist, and an endocrine surgeon is appropriate to guide management. If mild autonomous cortisol excess is present in this patient who has obesity and hypertension, adrenalectomy might result in improvement in her blood pressure and weight, although data are limited. If biochemical testing indicates that the tumor is nonfunctional, given that it is smaller than 4 cm in diameter and has an attenuation of less than 10 Hounsfield units on unenhanced CT, I would recommend no further testing, except in the unlikely case that clinical features of hormonal excess develop.

No potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

I thank Ms. Rebecca Gaw (Stanford University) for her help with drafting and organizing an earlier version of the manuscript, Dr. Ryan L. Brunsing (Department of Radiology, Stanford University) for the analysis of the imaging features, and Drs. Andr   Lacroix (Centre Hospitalier de l'Universit   de Montr  al) and Quan-yang Duh (University of California, San Francisco) for their helpful comments on the initial draft of the manuscript.

REFERENCES

1. Young WF Jr. The incidentally discovered adrenal mass. *N Engl J Med* 2007; 356:601-10.
2. Muth A, Hammarstedt L, Hellstr  m M, Sigurdsson H, Almqvist E, W  nberg B. Cohort study of patients with adrenal lesions discovered incidentally. *Br J Surg* 2011;98:1383-91.
3. Sherlock M, Scarsbrook A, Abbas A, et al. Adrenal incidentaloma. *Endocr Rev* 2020;41:775-820.
4. Papanicolaou I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. *JAMA* 2018;319:1024-39.
5. Kebebew E, ed. Management of adrenal masses in children and adults. Cham, Switzerland: Springer, 2017.
6. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. *Eur J Endocrinol* 2003;149:273-85.
7. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. *J Clin Endocrinol Metab* 2000;85:637-44.
8. Lam K-Y, Lo C-Y. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. *Clin Endocrinol (Oxf)* 2002;56:95-101.
9. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology clinical practice guideline in collaboration

- with the European Network for the Study of Adrenal Tumors. *Eur J Endocrinol* 2016;175:G1-G34.
10. Sbardella E, Minnetti M, D'Aluisio D, et al. Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. *Eur J Endocrinol* 2018;178:501-11.
 11. Ferreira L, Oliveira JC, Palma I. Screening Tests for hypercortisolism in patients with adrenal incidentaloma. *J Endocrinol Metab* 2018;8:62-8.
 12. Chiodini I, Torlontano M, Carnevale V, et al. Bone loss rate in adrenal incidentalomas: a longitudinal study. *J Clin Endocrinol Metab* 2001;86:5337-41.
 13. Valli N, Catargi B, Ronci N, et al. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. *Eur J Endocrinol* 2001;144:401-8.
 14. Denny MC, Annamalai AK, Prankerd-Smith O, et al. Low DHEAS: a sensitive and specific test for the detection of subclinical hypercortisolism in adrenal incidentalomas. *J Clin Endocrinol Metab* 2017;102:786-92.
 15. Elhassan YS, Alahdab F, Prete A, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. *Ann Intern Med* 2019;171:107-16.
 16. Morelli V, Palmieri S, Lania A, et al. Cardiovascular events in patients with mild autonomous cortisol secretion: analysis with artificial neural networks. *Eur J Endocrinol* 2017;177:73-83.
 17. Patrova J, Kjellman M, Wahrenberg H, Falhammar H. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center. *Endocrine* 2017;58:267-75.
 18. Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. *Lancet Diabetes Endocrinol* 2014;2:396-405.
 19. Park J, De Luca A, Dutton H, Malcolm JC, Doyle M-A. Cardiovascular outcomes in autonomous cortisol secretion and non-functioning adrenal adenoma: a systematic review. *J Endocr Soc* 2019;3:996-1008.
 20. Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. *J Clin Endocrinol Metab* 2014;99:4462-70.
 21. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. *Ann Surg* 2009;249:388-91.
 22. Perysinakis I, Marakaki C, Avlonitis S, et al. Laparoscopic adrenalectomy in patients with subclinical Cushing syndrome. *Surg Endosc* 2013;27:2145-8.
 23. Iacobone M, Citton M, Viel G, et al. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing's syndrome. *Surgery* 2012;152:991-7.
 24. Zeiger MA, Thompson GB, Duh Q-Y, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas: executive summary of recommendations. *Endocr Pract* 2009;15:450-3.
 25. Tabarin A, Bardet S, Bertherat J, et al. Exploration and management of adrenal incidentalomas. *Ann Endocrinol (Paris)* 2008;69:487-500.
 26. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. *Eur J Endocrinol* 2011;164:851-70.
 27. Lee JM, Kim MK, Ko SH, et al. Clinical guidelines for the management of adrenal incidentaloma. *Endocrinol Metab (Seoul)* 2017;32:200-18.
 28. Canu L, Van Hemert JAW, Kerstens MN, et al. CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma. *J Clin Endocrinol Metab* 2019;104:312-8.
 29. Buitenwerf E, Korteweg T, Visser A, et al. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. *Eur J Endocrinol* 2018;178:431-7.
 30. Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2014;99:1915-42.
 31. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2016;101:1889-916.
 32. Reznik Y, Amar L, Tabarin A. SFE/SFHTA/AFCE consensus on primary aldosteronism. 3. Confirmatory testing. *Ann Endocrinol (Paris)* 2016;77:202-7.
 33. Bancos I, Tamhane S, Shah M, et al. Diagnosis of endocrine disease: the diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. *Eur J Endocrinol* 2016;175:R65-R80.
 34. Dinnes J, Bancos I, Ferrante di Ruffano L, et al. Management of endocrine disease: imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. *Eur J Endocrinol* 2016;175:R51-R64.
 35. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (incidentaloma). *NIH Consensus State Sci Statements* 2002;19(2):1-25.
 36. Sturgeon C, Shen WT, Clark OH, Duh Q-Y, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? *J Am Coll Surg* 2006;202:423-30.
 37. Platzek I, Sieron D, Plodeck V, Borkowetz A, Laniado M, Hoffmann RT. Chemical shift imaging for evaluation of adrenal masses: a systematic review and meta-analysis. *Eur Radiol* 2019;29:806-17.
 38. Buitenwerf E, Berends AMA, van Asselt ADI, et al. Diagnostic accuracy of computed tomography to exclude pheochromocytoma: a systematic review, meta-analysis, and cost analysis. *Mayo Clin Proc* 2019;94:2040-52.
 39. Kim S-J, Lee S-W, Pak K, Kim I-J, Kim K. Diagnostic accuracy of ¹⁸F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. *Br J Radiol* 2018;91(1086):20170520.
 40. Bourdeau I, El Ghorayeb N, Gagnon N, Lacroix A. Management of endocrine disease: differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas. *Eur J Endocrinol* 2018;179:R57-R67.
 41. Falhammar H, Torpy DJ. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency presenting as adrenal incidentaloma: a systematic review and meta-analysis. *Endocr Pract* 2016;22:736-52.

Copyright © 2021 Massachusetts Medical Society.